Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 6/2016

IN VITRO P-GP EXPRESSION AFTER ADMINISTRATION OF CNS ACTIVE DRUGS

ALINA CRENGUȚA NICOLAE 1#, ANDREEA LETIȚIA ARSENE 2#*, VLAD VUȚĂ 3#, DANIELA ELENA POPA 4#, CARMEN ADELLA SÎRBU 5#, GEORGE TRAIAN ALEXANDRU BURCEA DRAGOMIROIU 4#, ION-BOGDAN DUMITRESCU 6#, BRUNO ȘTEFAN VELESCU 7#, ELIZA GOFIȚĂ 8#, CRISTINA MANUELA DRĂGOI 1#

1.“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Biochemistry, 6 Traian Vuia Street, Bucharest, Romania
2 .“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Microbiology, 6 Traian Vuia Street, Bucharest, Romania
3 .Institute for Diagnosis and Animal Health, Department of Virology, Bucharest, Romania
4 .“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Drug Control, 6 Traian Vuia Street, Bucharest, Romania
5 .“Carol Davila” Central University Emergency Military Hospital, Department of Neurology, 134 Calea Plevnei Street, Bucharest, Romania
6 .“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Physics and Informatics, 6 Traian Vuia Street, Bucharest, Romania
7 .“Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, 6 Traian Vuia Street, Bucharest, Romania
8 .University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Toxicology, 2 Petru Rareș Street, 200349, Craiova, Romania

Download Full Article PDF

P-glycoprotein (P-gp) is a transmembrane efflux pump, part of the ABC transporters family (ATP-binding cassette) playing an important role in the absorption (intestine), distribution (CNS and white blood cells) and elimination (liver, kidney) of xenobiotics, as well as endogenous products, present in various cell types. The clinical significance of P-gp is depicted by drug resistance of the cells, which ultimately leads to compromising therapy. Modulating the expression of P-gp transporters could be an effective therapeutic strategy in mitigating the side effects of neuronal drugs, improving pharmacokinetic and pharmacodynamic properties of the substrates whose effectiveness is limited by P-gp. In the present study we assessed the influence of several CNS active drugs (valproic acid, risperidone, thioridazine, fluoxetine, lithium), as well as combinations of these drugs associated with quinidine (a classic inhibitor of the P-gp efflux pump), on the expression of P-glycoprotein, by means of quantitative indirect immunofluorescence. We assessed the expression of P-gp in vitro, on the murine neuroblastoma cell line N2a, after the administration of these drugs, as well as their associations. The obtained results revealed significant changes in the expression of P-gp in the neuroblastoma cell line, denoting the inhibition of the efflux pump. An absolute novelty, for the current research in the pharmacotherapy field, is the synergistic in vitro potention of the inhibitory effect on the expression of P-gp, revealed by two of the studied drugs: valproic acid and thioridazine. Of all five studied drugs (valproic acid, risperidone, thioridazine, fluoxetine, lithium), lithium showed the strongest effect on the expression of P-gp.